Review Articles, News & Views, Perspectives, Hypotheses, Analyses and Review in 2004

Cyclodextrin-based pharmaceutics: past, present and future

• Mark E. Davis
• Marcus E. Brewster

Development of TGF-β signalling inhibitors for cancer therapy

• Jonathan M. Yingling
• Kerry L. Blanchard
• J. Scott Sawyer

Making protein interactions druggable: targeting PDZ domains

• Kumlesh K. Dev

Challenges in bringing the bench to bedside in drug development for sle

• Joan T. Merrill
• Doruk Erkan
• Jill P. Buyon

Strategies to overcome resistance to targeted protein kinase inhibitors

• Henrik Daub
• Katja Specht
• Axel Ullrich

Principles for modulation of the nuclear receptor superfamily

• Hinrich Gronemeyer
• Jan-Åke Gustafsson
• Vincent Laudet

Docking and scoring in virtual screening for drug discovery: methods and applications

• Douglas B. Kitchen
• Hélène Decornez
• Jürgen Bajorath

Drugs as materials: valuing physical form in drug discovery

• Colin R. Gardner
• Christopher T. Walsh
• Örn Almarsson

Molecular, cellular and functional imaging of atherothrombosis

• Robin P. Choudhury
• Valentin Fuster
• Zahi A. Fayad

Functional genomics to new drug targets

• Richard Kramer
• Dalia Cohen

Bradykinin receptor ligands: therapeutic perspectives

• François Marceau
• Domenico Regoli

New drugs for asthma

• Peter J. Barnes

Glycomics: a pathway to a class of new and improved therapeutics

• Zachary Shriver
• S. Raguram
• Ram Sasisekharan

The role of the medicinal chemist in drug discovery — then and now

• Joseph G. Lombardino
• John A. Lowe III

Prion diseases — close to effective therapy?

• Neil R. Cashman
• Byron Caughey

Nanosuspensions in drug delivery

• Barrett E. Rabinow

Technology platforms for pharmacogenomic diagnostic assays

• Walter H. Koch

The endocannabinoid system and its therapeutic exploitation

• Vincenzo Di Marzo
• Maurizio Bifulco
• Luciano De Petrocellis

Pharmacogenomics: bench to bedside

• Richard Weinshilboum
• Liewei Wang

Drug repositioning: identifying and developing new uses for existing drugs

• Ted T. Ashburn
• Karl B. Thor